Goettingen

• Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel … Ended recruitment
  2024-515783-31-00 5 2018-08-24 Newly Diagnosed Multiple Myeloma
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended recruitment
  2023-509856-32-00 5 2018-07-15 acute lymphoblastic leukemia in children and adolescents
• MB-CART19.1 r/r CD19+ BCM Ended recruitment
  2024-513334-38-00 1 2018-05-15 Refractory/relapsed B-NHL
• Obinutuzumab in marginal zone lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (OLYMP-1) Ended recruitment
  2024-517476-38-00 4 2018-05-14 Marginal Zone Lymphoma
• International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended recruitment
  2024-513070-21-00 4 2018-02-15 Relapsed Acute Lymphoblastic Leukemia (ALL)
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia
• B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and … Ended recruitment
  2023-505509-18-00 5 2017-07-12 mature aggressive B-cell lymphoma and leukemia in children and adolesc
• Study of Tumor Alterations Responsive to Targeting Receptor Kinases-2 Ended recruitment
  2023-505034-10-00 4 2016-08-01 Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• A two-year, double-blind, randomized, multicenter, active controlled Core Phase study to evaluate the safety and efficacy of fingolimod admi … Ended recruitment
  2023-507556-68-00 5 2013-07-26 Multiple Sclerosis
• To Investigate whether the combination of molidustat and an IDH1 inhibitor (ivosidenib) effectively inhibits leukaemia cells in patients wit … Halted
  2024-514051-15-00 7 2023-07-10 Adult patients with relapsed or refractory IDH1-mutated AML or relapse
• Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacok … Ended
  2024-510582-42-02 4 2025-08-14 Acute graft versus host disease (aGvHD)
• Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma Ended
  2024-510972-19-00 4 2025-03-13 Primary mediastinal large B-cell lymphoma (PMBCL)
• A phase I/II trial of D,L-MEthadone and mFOLFOX6 in treatment of advanced colorectal cancer (MEFOX) Ended
  2024-519509-37-00 9 2025-02-25 Patients with advanced, histologically confirmed, metastatic colorecta
• A Safety and Tolerability Study of VRDN-001 in Persons with Thyroid Eye Disease (TED) Ended
  2023-507563-19-00 5 2024-11-05 Thyroid eye disease
• A Phase 2, multicentre, open-label study of sonelokimab in patients with moderate-to-severe pustulosis palmoplantaris Ended
  2024-513305-32-00 4 2024-10-29 Palmoplantar Pustulosis
• A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended
  2023-509198-22-00 5 2024-10-21 Thyroid Eye Disease (TED)
• Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome Ended
  2023-509638-20-00 4 2024-09-30 Alport Syndrome
• A study of aficamten (CK-3773274) in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (ACACIA) Ended
  2023-505797-15-00 5 2024-09-13 SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
• CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3 Ended
  2024-510863-50-00 4 2024-08-30 Neuroendocrine Neoplasia Neuroendocrine Tumor
• Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia Ended
  2023-508819-23-00 3 2024-07-24 Primary immune thrombocytopenia (ITP)
• Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome … Ended
  2024-511628-16-00 4 2024-07-18 Post Covid Syndrome (PCS)
• An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal … Ended
  2023-507350-33-00 5 2024-06-25 Thyroid eye disease
• A randomized, multicenter, open-label trial comparing the effectiveness of Inclisiran to bempedoic acid on LDL cholesterol (LDL-C) lowering … Ended
  2024-511076-32-00 6 2024-06-21 Hypercholesterolemia

Showing 217–240 of 293 trials